Monoclonal antibody (mAb) therapeutics have become a major part of the biopharmaceutical landscape, with oncology representing one of the most important areas of development. Alongside full-length monoclonal antibodies, researchers and biopharmaceutical companies are advancing next-generation antibody products, including antibody-drug conjugates (ADCs), antibody fragments, antibody-like proteins, and engineered antibodies.
The growing range of antibody-based therapies, together with continued interest in biosimilars, is increasing the need for efficient and scalable development strategies. Accelerating mAb development requires approaches that optimize processes, reduce development timelines, and support a smooth transition from early development to commercial manufacturing.
Early-Stage mAb Optimization
Bringing a new mAb to market can involve significant challenges across development and manufacturing. Addressing these challenges early can help improve process understanding, productivity, and scalability.
- Media development and optimization are important for improving productivity, increasing titers, and supporting consistent product quality. Advanced media options include animal origin-free (AOF) and chemically defined (CD) media, available in different formats and designed for use with specific cell lines and process requirements.
- Innovative feeds, reagents, and additives can help optimize cell culture processes, reduce variability, and improve productivity. Evaluating these components during early development can provide useful information before a process moves to larger scales.
- Small-scale rapid prototyping can help assess the manufacturability and scalability of a formulation before cGMP scale-up. It can also be used to evaluate changes to raw materials, test new materials, and assess different formulation formats, such as converting a liquid formulation to a dry powder.
- Analytical platforms can help developers identify process issues, evaluate product quality, and understand how process changes affect performance. Applying analytical data throughout development can support more consistent scale-up and help reduce unnecessary development costs.
- The application of multi-omics, including proteomics and metabolomics, is providing new insights into cellular pathways involved in biomanufacturing. These approaches can help researchers understand how cells use media components and identify opportunities to optimize cell culture conditions.
You might also be interested in: Accelerating Biologics Manufacturing
During Scale-Up
As a mAb process moves toward larger-scale manufacturing, selecting a medium that fits the bioprocessing objectives becomes increasingly important. Both liquid and dry powdered medium (DPM) formats can offer advantages depending on the manufacturing strategy.
Liquid and dry formats have different operational and logistical considerations. Dry media can offer advantages for transportation and storage because of its longer shelf life and lower shipping volume, although reconstitution adds an additional process step. Liquid media are ready to use and can simplify preparation, but they may have higher transportation requirements and shorter shelf lives.
These factors should be evaluated alongside cell culture performance, supply chain requirements, manufacturing scale, and overall process economics.
Late-Stage Production of mAbs
As mAb processes move toward late-stage development and manufacturing, equipment selection, automation, data management, and process control become increasingly important. Single-use bioreactors can provide flexibility and may offer advantages for certain mAb manufacturing strategies, particularly in multiproduct facilities.
Digitalization can also support more efficient scale-up and manufacturing. Integrated systems that capture process data, maintain information integrity, and enable streamlined data transfer can improve visibility across the manufacturing workflow and support more informed decision-making.
At this stage, it is also important to work with a partner that can bring these capabilities together across the development and manufacturing process. 53Biologics supports mAb programs through process characterization, advanced analytics, product development, process optimization, technology transfer, risk mitigation, and timeline management.
You might also be interested in: Biologics CDMO: Why You Need One
Optimizing mAb Development with the Right Support
Moving a therapeutic antibody from development toward commercialization requires more than manufacturing capacity. The right development and scale-up partner should understand how process characterization, product development, technology transfer, risk management, and manufacturing timelines interact.
A capable partner can help identify process risks early, evaluate opportunities for simplification, and establish a development strategy that supports the transition to larger-scale manufacturing. Experience with cGMP sourcing, process optimization, analytical development, and technology transfer can also help reduce avoidable delays as the program progresses.
With an experienced team and large-scale manufacturing facilities, 53Biologics supports biopharmaceutical companies throughout mAb development and manufacturing. Our integrated approach is designed to provide flexibility as programs evolve while supporting process consistency, quality, and efficient scale-up.
From early process development to manufacturing, 53Biologics can help biopharma companies address development challenges, manage supply considerations, and improve process productivity for their mAb programs.
Want to discuss your mAb manufacturing program? Contact our mAb manufacturing team.